Mateon Therapeutics   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: South San Francisco CA United States (1988)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2005
NCT00113438
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Mateon Therapeutics | OXiGENE